Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer

References

• Global Cancer Observatory [Internet]. Sweden. 2018; [cited 2021 Aug 26]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/752-sweden-fact-sheets.pdf.
   Google Scholar
• Carrato A, Falcone A, Ducreux M, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015;46(3):201–211.
   PubMedGoogle Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: five year follow-up. J Clin Oncol. 2020;38(15_suppl):4516–4516.
   Web of Science ®Google Scholar
• Thibodeau S, Voutsadakis I. FOLFIRINOX chemotherapy in metastatic pancreatic cancer: a systematic review and meta-analysis of retrospective and phase II studies. J Clin Med. 2018;7:7.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):JCO2001364–3230.
   Web of Science ®Google Scholar
• Ryan DP. Chemotherapy for advanced exocrine pancreatic cancer. UpToDate [internet]. 2021; [Jun 30. cited 2021 Jul 25]. Available from: https://www.uptodate.com/contents/initial-systemic-chemotherapy-for-metastatic-exocrine-pancreatic-cancer.
   Google Scholar
• Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87.
   PubMed Web of Science ®Google Scholar
• Ioka T, Komatsu Y, Mizuno N, et al. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017;116(4):464–471.
   PubMed Web of Science ®Google Scholar
• Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989–995.
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (off) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676–1681.
   PubMed Web of Science ®Google Scholar
• Walker E, Ko A. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014;20(9):2224–2236.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Firwana B, Wang Z, et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Cancer. 2017;123(23):4680–4686.
   PubMed Web of Science ®Google Scholar
• Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914–3920.
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423–2429.
   PubMed Web of Science ®Google Scholar
• Dadi N, Stanley M, Shahda S, et al. Impact of Nab-Paclitaxel-based second-line chemotherapy in metastatic pancreatic cancer. Anticancer Res. 2017;37(10):5533–5539.
   PubMed Web of Science ®Google Scholar
• Sinn M, Dälken L, Striefler JK, et al. Second-line treatment in pancreatic cancer patients: who profits?—results from the CONKO study group. Pancreas. 2016;45(4):601–605.
   PubMed Web of Science ®Google Scholar
• Bao Y, Maciejewski RC, Garrido MM, et al. Chemotherapy use, end-of-life care, and costs of care among patients diagnosed with stage IV pancreatic cancer. J Pain Symptom Manag. 2018;55(4):1113–1121.e3.
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–29.
   PubMed Web of Science ®Google Scholar
• Pant S, Martin LK, Geyer S, et al. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014;120(12):1780–1786.
   PubMed Web of Science ®Google Scholar
• Bittoni A, Pellei C, Lanese A, et al. Prognostic factors in advanced pancreatic cancer patients receiving second-line chemotherapy: a single institution experience. Transl Cancer Res. 2018;7(5):1190–1198.
   Web of Science ®Google Scholar
• Tas F, Sen F, Odabas H, et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol. 2013;18(5):839–846.
   PubMed Web of Science ®Google Scholar
• Nemer L, Krishna SG, Shah ZK, et al. Predictors of pancreatic cancer-associated weight loss and nutritional interventions. Pancreas. 2017;46(9):1152–1157.
   PubMed Web of Science ®Google Scholar
• Gränsmark E, Bågenholm Bylin N, Blomstrand H, et al. Real world evidence on second-line palliative chemotherapy in advanced pancreatic cancer. Front Oncol. 2020;10:1176.
   PubMed Web of Science ®Google Scholar
• Näppä U, Lindqvist O, Rasmussen BH, et al. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22(11):2375–2380.
   PubMed Web of Science ®Google Scholar
• Wright AA, Zhang B, Keating NL, et al. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219.
   PubMed Web of Science ®Google Scholar
• Harrington SE, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough?” JAMA. 2008;299(22):2667–2678.
   PubMed Web of Science ®Google Scholar
• Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol. 2012;30(4):394–400.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–1724.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14(2):671–679.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Dow LA, Virago EA, et al. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol. 2011;9(2):79–86.
   PubMedGoogle Scholar